JCRB1795 BALM-16
Cell information
Cell type：general cells (View Pricing Information)
| JCRB No. | JCRB1795 | Cell Name | BALM-16 |
|---|---|---|---|
| Profile | B cell leukemia cell line, Ig negative, ALL-L3 cell line, t(8;22)(q24;q11), hypercalcemia, mRNA expression of PTHrP | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | M | Age | 42-year-old |
| Identity | not done | Tissue for Primary Cancer | peripheral blood |
| Case history | Acute lymphoblastic leukemia (ALL), hypercalcemia | Metastasis | |
| Tissue Metastasized | Genetics | Karyotype information included in established papers | |
| Life Span | infinite | Crisis PDL | |
| Morphology | lymphoblast-like | Character | lacking expression of immunoglobulin chains. |
| Classify | tumor | Established by | Matsuo Y |
| Registered by | Fujisaki Cell Center, Hayashibara Biochemical Laboratories, Inc | Regulation for Distribution | |
| Comment | Year | 2019 | |
| Medium | RPMI1640 medium with 10% featal bovine serum. | Methods for Passages | dilution (split ratio 1:2-1:3)/week |
| Cell Number on Passage | Race | Japanese | |
| CO2 Conc. | 5% | Tissue Sampling | peripheral blood |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:9447837 | A novel ALL-L3 cell line, BALM-16, lacking expression of immunoglobulin chains derived from a patient with hypercalcemia. Matsuo Y,MacLeod RA,Kojima K,Kuwahara K,Sakata A,Drexler HG,Nishizaki C,Fukuda S,Inoue Y,Sezaki T,Sakaguchi N,Orita K Leukemia. 1997 Dec;11(12):2168-74 |
| Images |
|---|
      |
LOT Information
Viability/Growth rate/Cell number are represented as actual values measured at lot presentation in JCRB, but are not guaranteed values. Additionally, the doubling time is a rough value measured during passages.| Cell No. | JCRB1795 | Cell Name | BALM-16 |
|---|---|---|---|
| LOT No. | 05252019 | Lot Specification | distribution |
| Medium | RPMI1640 medium(GIBCO) with 10% heat inactivated fetal bovine serum(SIGMA Cat.# 172012, Lot 12J396) | Temperature | 37 C |
| Cell Density at Seeding | 0.8-1.0x10^6 cells/ml | Methods for Passages | Dilution(1/3-1/8) |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 7.7x10^6 |
| Viability at cell freezing (%) | 97.6 | Antibiotics Used | free |
| Passage Number | p3* | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:11 D13S317:12 D7S820:10 D16S539:12 VWA:18,19 TH01:7,9 AM:X,Y TPOX:8,11 CSF1PO:9,11 |
| Adhesion | No | Exoteric Gene | NT |
| Medium for Freezing | BAMBANKER(LYMPHOTEC Inc.,CS-02-001,NIPPON Genetics Co., LTD) | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | NT | Additional information |
| Images |
|---|
|
|